Novavax Initiates Animal Testing of H7N9 VLP Vaccine

Emergence of Avian Influenza A(H7N9)Novavax, Inc. this week announced it has completed purification of a virus-like particle (VLP) vaccine candidate for the emerging H7N9 influenza and has initiated animal immunogenicity and efficacy studies.

The company began work on the strain in early April. Analysis and optimization of the gene sequences for the key viral hemagglutinin (HA) and Continue reading

Medicago Produces VLP Vaccine Candidate for Emerging H7N9 Virus

Biodefense Vaccine ProgramMedicago Inc., a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), this week announced that it has successfully produced a new VLP vaccine candidateĀ for the H7N9 virus that is responsible for the current influenza outbreak inĀ China.

“To our knowledge, Medicago Continue reading

Simian Vaccine Evaluation Unit Contract Awards

HIV Vaccine Research (NIAID)The National Institute for Allergy and Infectious Diseases has made three contract awards for the Simian Vaccine Evaluation Unit (SVEU) effort for facilities and resources to conduct non-human primate immunogenicity research and pilot studies for new antivirals and vaccines.

The SVEU contracts will provide non-human primate (NHP) resources that primarily support Continue reading

Soligenix and Intrexon Partner to Develop Burkholderia Countermeasure

Burkholderia pseudomalleiSoligenix, Inc., announced this week it will jointly develop a treatment for Melioidosis, an infectious disease caused by a Gram-negative bacterium, Burkholderia pseudomallei, through a worldwide exclusive collaboration with Intrexon.

Burkholderia pseudomallei and the closely related Burkholderia mallei are considered Continue reading